Effects of eplerenone vs losartan on endothelial function and Rho-associated kinase activity in patients with essential hypertension

Trial Profile

Effects of eplerenone vs losartan on endothelial function and Rho-associated kinase activity in patients with essential hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2011

At a glance

  • Drugs Eplerenone (Primary) ; Losartan (Primary)
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Dec 2011 New trial record
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top